U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H46O2
Molecular Weight 366.6208
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NERVONIC ACID

SMILES

CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O

InChI

InChIKey=GWHCXVQVJPWHRF-KTKRTIGZSA-N
InChI=1S/C24H46O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26/h9-10H,2-8,11-23H2,1H3,(H,25,26)/b10-9-

HIDE SMILES / InChI

Molecular Formula C24H46O2
Molecular Weight 366.6208
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Nervonic acid is a long chain unsaturated fatty acid that is enriched in sphingomyelin. It consists of choline, sphingosine, phosphoric acid, and fatty acid. Nervonic acid may enhance the brain functions and prevent demyelination (Chemical Land21). Research shows that there is negative relationship between nervonic acid and obesity-related risk factors. Demyelination in adrenoleukodystrophy (ALD) is associated with an accumulation of very long chain saturated fatty acids stemming from a genetic defect in the peroxisomal beta oxidation system responsible for the chain shortening of these fatty acids. Sphingolipids from post mortem ALD brain have decreased levels of nervonic acid, 24:1(n-9), and increased levels of stearic acid, 18:0. Nervonic acid (C24:1), a component of membrane sphingolipids and phosphatidylethanolamines, may be a useful predictor of chronic kidney disease mortality and diabetes. Nervonic acid oils are being studied for pharmaceutical, nutraceutical and industrial applications. Nervonic acid is a major component of Lunaria oil. There is increasing evidence that dietary supplementation with nervonic acid is healthy for babies and infants during the early stage of brain development. Nervonic acid has been reported to reduce the shaking associated with Parkinson’s disease and the numbness caused by multiple sclerosis. It also has potential for treating schizophrenia and reducing early Alzheimer’s symptoms.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
4.0 µM [Ki]
0.3 µM [Ki]
1.2 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown
Preventing
Unknown

Doses

PubMed

Sample Use Guides

In Vivo Use Guide
Since Nervonic acid is almost insoluble in water, it often sold in the form of capsules. Generally speaking, two capsules orally every time, and two doses or two times a day, one in the morning, and the other in the evening. The recommended dosage ranges from 200mg to 300mg of pure nervonic acid.
Route of Administration: Oral
In Vitro Use Guide
Nervonic acid (NA) most effectively inhibited calf DNA polymerase a activity; its minimum inhibitory concentration MIC was 2 uM. NA 10 uM completely suppressed the activities of both polymerases (calf DNA polymerase a and rat DNA polymerase b).
Substance Class Chemical
Record UNII
91OQS788BE
Record Status Validated (UNII)
Record Version